Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Abdul Hai Mansoor

Hematology & Oncology Portland, OR Medical Doctor

NPI 1790934149 CMS profile 1324585

3600 N Interstate Ave, Portland, OR 97227

Open in the dashboard

General payments

$0

None reported · program years 2019–2024

Research payments

$7,192

Paid to them · 3 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,500,742 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Abdul Hai Mansoor of Portland, OR is reported in the CMS Open Payments database as having received $0 across 0 general payments and $7,192 in research payments paid to them. Separately, studies naming them as principal investigator received $3,500,742 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 66th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $6,363 2
2019 Research $829 1

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,025

Median for Hematology: 273

Drug cost

$6,440,473

Median for Hematology: $800,183

Branded share of claims

25.8%

Median for Hematology: 39.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lenalidomide Generic 193 $2,418,468
Pomalyst Pomalidomide Brand 55 $1,364,792
Brukinsa Zanubrutinib Brand 59 $777,065
Jakafi Ruxolitinib Phosphate Brand 74 $628,017
Tasigna Nilotinib Hcl Brand 23 $447,567
Calquence Acalabrutinib Maleate Brand 23 $330,764
Promacta Eltrombopag Olamine Brand 13 $135,178
Alvaiz Eltrombopag Choline Brand 25 $127,969
Venclexta Venetoclax Brand 25 $93,597
Xarelto Rivaroxaban Brand 40 $26,740

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 799 Part D prescribers listed as Hematology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$21,394

Medicare's payments for the services billed

Medicare patients

12

Average age 67

Services billed

511

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record